Lista de obras -

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

artículo científico publicado en 2005

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

artículo científico publicado en 2000

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo

artículo científico publicado en 1995

An agarose spot chemotaxis assay for chemokine receptor antagonists.

artículo científico publicado en 2011

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

artículo científico publicado en 2012

Antitumour prodrug development using cytochrome P450 (CYP) mediated activation

artículo científico publicado en 1999

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

artículo científico publicado en 2003

Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

artículo científico publicado en 2002

CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.

artículo científico publicado en 2013

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins

artículo científico publicado en 2013

Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using 18O stable isotope labeling

artículo científico publicado en 2007

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells

artículo científico publicado en 1996

DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents.

artículo científico publicado en 2005

Design and synthesis of a DNA-crosslinking azinomycin analogue.

artículo científico publicado en 2005

Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases ⬇️

artículo científico publicado el 27 de julio de 2010

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.

artículo científico publicado en 2005

Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists

artículo científico publicado en 2013

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

artículo científico publicado en 2000

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

artículo científico publicado en 2000

Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation

artículo científico publicado en 1996

Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry

artículo científico publicado en 2007

Improved preparation and detection of cytochrome P450 isoforms using MS methods

artículo científico publicado en 2010

Intramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactones

artículo científico publicado en 2016

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

artículo científico publicado en 1998

Microstructural investigation using synchrotron radiation X-ray microtomography reveals taste-masking mechanism of acetaminophen microspheres

artículo científico publicado en 2015

Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry

artículo científico publicado en 2009

NCAM polysialylation during adherence transitions: live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7.

artículo científico publicado en 2013

Nipple aspirate fluid-A liquid biopsy for diagnosing breast health.

artículo científico publicado en 2017

Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration

artículo científico publicado en 2013

Protein deregulation associated with breast cancer metastasis

artículo científico

RGD-Binding Integrins in Head and Neck Cancers

artículo científico publicado en 2017

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

artículo científico

Rational Development of Novel Activity Probes for the Analysis of Human Cytochromes P450

artículo científico publicado en 2016

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

artículo científico publicado en 2013

Resistance in cancer: a target for drug discovery.

artículo científico publicado en 2004

Royal academy of medicine in Ireland section of biomedical sciences

Spectral analysis of the DNA targeting bisalkylaminoanthraquinone DRAQ5 in intact living cells

artículo científico publicado en 2006

Steve Paschal Kenyon, M.D.

artículo científico publicado en 1952

Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.

artículo científico

Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides

artículo científico publicado en 2006

Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.

artículo científico publicado en 2016

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

artículo científico publicado en 2001

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

artículo científico publicado en 2002

The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.

artículo científico publicado en 2017

The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models.

scientific article published on 05 August 2016

Truncated azinomycin analogues intercalate into DNA.

artículo científico publicado en 2005

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

artículo científico publicado en 2006

Use of the hollow fiber assay for the evaluation of DNA damaging agents.

artículo científico publicado en 2011

Lista de obras de

A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.

AQ4N: a new approach to hypoxia-activated cancer chemotherapy

AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo

An agarose spot chemotaxis assay for chemokine receptor antagonists.

Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.

Antitumour prodrug development using cytochrome P450 (CYP) mediated activation

Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N.

Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy

CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer.

Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins

Comparative cytochrome P450 proteomics in the livers of immunodeficient mice using 18O stable isotope labeling

DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells

DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents.

Design and synthesis of a DNA-crosslinking azinomycin analogue.

Development of a Novel Tumor-Targeted Vascular Disrupting Agent Activated by Membrane-Type Matrix Metalloproteinases ⬇️

Development of nonsymmetrical 1,4-disubstituted anthraquinones that are potently active against cisplatin-resistant ovarian cancer cells.

Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists

Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation

Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry

Improved preparation and detection of cytochrome P450 isoforms using MS methods

Intramolecular thermal stepwise [2 + 2] cycloadditions: investigation of a stereoselective synthesis of [n.2.0]-bicyclolactones

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

Microstructural investigation using synchrotron radiation X-ray microtomography reveals taste-masking mechanism of acetaminophen microspheres

Multiple-approaches to the identification and quantification of cytochromes P450 in human liver tissue by mass spectrometry

NCAM polysialylation during adherence transitions: live cell monitoring using an antibody-mimetic EGFP-endosialidase and the viability dye DRAQ7.

Nipple aspirate fluid-A liquid biopsy for diagnosing breast health.

Pharmacological inhibition of polysialyltransferase ST8SiaII modulates tumour cell migration

Protein deregulation associated with breast cancer metastasis

RGD-Binding Integrins in Head and Neck Cancers

RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

Rational Development of Novel Activity Probes for the Analysis of Human Cytochromes P450

Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity.

Resistance in cancer: a target for drug discovery.

Royal academy of medicine in Ireland section of biomedical sciences

Spectral analysis of the DNA targeting bisalkylaminoanthraquinone DRAQ5 in intact living cells

Steve Paschal Kenyon, M.D.

Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.

Synthesis of DNA-directed pyrrolidinyl and piperidinyl confined alkylating chloroalkylaminoanthraquinones: potential for development of tumor-selective N-oxides

Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression.

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N.

The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors.

The use of thermographic imaging to evaluate therapeutic response in human tumour xenograft models.

Truncated azinomycin analogues intercalate into DNA.

Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.

Use of the hollow fiber assay for the evaluation of DNA damaging agents.